Please assess the completion status of the following clinical trial:

Trial Title: Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Confirmed diagnosis of symptomatic multiple myeloma~  * Durie Salmon stage 2 or higher~ * Previously untreated multiple myeloma (including immunomodulatory drugs such as thalidomide) with the exception of bisphosphonates~* Evaluable or measurable disease, as defined by at least one of the following:~  * Serum monoclonal protein ≥ 1 g/dL (measurable disease)~ * Urine monoclonal protein ≥ 200 mg/24 hours by protein electrophoresis (measurable disease)~ * Serum-free light chains (FLC) ≥ 10 mg/dL, kappa or lambda, accompanied by an abnormal kappa/lambda ratio~Serum FLC's should only be used for patients without measurable serum or urine m-spike~- Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease)~\* Patients diagnosed with smoldering myeloma or monoclonal gammopathy of undetermined significance are not eligible~PATIENT CHARACTERISTICS:~Inclusion criteria:~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1, or 2~  - ECOG PS of 3 will be allowed if secondary to pain in the opinion of the Investigator~* Total bilirubin normal OR direct bilirubin ≤ 2.0 mg/dL~* Alkaline phosphatase ≤ 3 times upper limit of normal (ULN)~* AST ≤ 3 times ULN~* Creatinine ≤ 3.5 mg/dL~* Absolute neutrophil count ≥ 1,000/mm³ without transfusion or growth factor~* Platelet count ≥ 100,000/mm³ without transfusion or growth factor~* Willingness and the physical and mental capability to provide written informed consent~* Willingness to return to Mayo Clinic Arizona/Princess Margaret Hospital for follow-up~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~Exclusion criteria:~* Peripheral sensory neuropathy ≥ grade 2 as defined by National Cancer Institute (NCI) Common Terminology for Common Adverse Events (CTCAE) version 3.0~* Known hypersensitivity to compounds containing boron or mannitol~* Active uncontrolled infection~* Severe cardiac comorbidity including but not limited to:~  * New York Heart Association class III or IV heart failure~ * History of myocardial infarction within the past 6 months~ * Uncontrolled angina or electrocardiographic (ECG) evidence of acute ischemia~ * Severe uncontrolled ventricular arrhythmias or ECG evidence of active conduction system abnormalities~ * Cardiac amyloidosis with hypotension (i.e., systolic blood pressure \< 100 mm Hg)~* Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent study compliance or completion of study treatment~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Prior high-dose corticosteroid therapy for 12 days or less is permitted for emergent complications from newly diagnosed multiple myeloma~* More than 14 days since prior investigational agents~* No concurrent steroids or any other anticancer agents or treatments~  - Patients may receive the equivalent of up to 20 mg prednisone per day for concurrent illness or adrenal replacement therapy~* Concurrent palliative radiotherapy for bony pain or fracture is allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).